Davide Corti

This inventor holds 51 USPTO granted patents and 34 published patent applications, plus 4 CIPO patents and 14 EPO patents, primarily in Neutralizing Antibodies. Top assignees: Humabs Biomed Sa, Medimmune Limited, Institute for Research in Biomedicine. Active years: 2016-2025.

USPTO Granted Patents = 51 (Patent Applications = 34)

% Patents Active = 98.0

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 14 (Patent Applications = 47)

Average Co-Inventor Count = 2.5

ph-index = 4

Forward Citations = 58(Granted Patents)

Forward Citations (Not Self Cited) = 26(Dec 10, 2025)

Company Filing History:

Institute for Research in Biomedicine

patents

4. 10 out of 3,688

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Vir Biotechnology, Inc.

patents

7. 2 out of 8,742

US Government as Represented by the Secretary of the Army

patents

8. 1 out of 15

The Pirbright Institute

patents

9. 1 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

Neutralizing Antibodies

Influenza

Hepatitis B

Zika Virus

Multispecific Antibodies

RSV

Rabies Virus

SARS-CoV-2

Recombinant Proteins

Immunogens

Anti-O1 Antibodies

Anti-O2 Antibodies

51 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12492240 - NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF (2025-12-09),

2. 12435113 - Prefusion PIV F immunogens and their use (2025-10-07),

3. 12404318 - Combination HBV therapy (2025-09-02),

4. 12325740 - Neutralizing anti-influenza B antibodies and uses thereof (2025-06-10),

5. 12312397 - Anti-O2 antibodies and uses thereof (2025-05-27),

6. 12304946 - Antibodies that neutralize hepatitis B virus and uses thereof (2025-05-20),

7. 12297258 - Antibodies againstspecies (2025-05-13),

8. 12233124 - Recombinant metapneumovirus f proteins and their use (2025-02-25),

9. 12037381 - Antibodies that potently neutralize hepatitis B virus and uses thereof (2024-07-16),

10. 12018068 - Anti-O1 antibodies and uses thereof (2024-06-25),

11. 11970527 - Antibody directed againstclumping factor A (ClfA) (2024-04-30),

12. 11932682 - Neutralizing anti-influenza A antibodies and uses thereof (2024-03-19),

13. 11926658 - Multispecific antibodies specifically binding to Zika virus epitopes (2024-03-12),

14. 11912757 - Antibodies specifically binding to Zika virus epitopes and uses thereof (2024-02-27),

15. 11845778 - Prefusion PIV F immunogens and their use (2023-12-19),

Title: **Davide Corti: Pioneering Innovations in Immunology**

Introduction

Davide Corti is an innovative inventor based in Bellinzona, Switzerland, renowned for his groundbreaking work in the field of immunology. With a remarkable portfolio of 44 patents, Corti's contributions have significantly advanced the development of therapeutics aimed at combatting viral infections.

Latest Patents

Corti's recent patents showcase his expertise in harnessing the immune response against viral pathogens. One of his latest inventions involves recombinant metapneumovirus F proteins and their applications. This patent details the use of stabilized metapneumovirus F proteins and nucleic acid molecules to generate an immune response in subjects, providing new avenues for the treatment and prevention of metapneumovirus infection.

Another significant patent concerns antibodies that effectively neutralize hepatitis B virus. This invention encompasses antibodies and their fragments that bind to critical regions of hepatitis B surface antigen (HBsAg) and inhibit both HBV and hepatitis delta virus (HDV) infections. The patent also discusses the potential uses of these antibodies in diagnosis, prevention, and therapy for hepatitis B and D, marking a substantial advancement in the management of these viral diseases.

Career Highlights

Throughout his career, Davide Corti has worked with esteemed companies such as Humabs Biomed SA and MedImmune Limited. His experience in these organizations has allowed him to refine his research skills and contribute to the development of therapeutic solutions that address some of the world's most pressing health challenges.

Collaborations

Corti has had the privilege of collaborating with distinguished professionals in his field, including Antonio Lanzavecchia and Ebony Benjamin. These partnerships have been instrumental in fostering innovation and advancing research in immunology.

Conclusion

In summary, Davide Corti stands out as a prominent figure in the realm of immunological research and patent innovation. His extensive work has the potential to transform the treatment landscape for viral infections, ultimately improving patient outcomes and contributing to public health advancements.